SGS Life Science Services, the leading pharmaceutical clinical and bioanalytical contract solutions provider, today announced that it is to invest in its Mumbai, India, facility, in a move which will see the current 1393 sq m laboratory more than double in size, to 3994 sq m. The expansion is being driven by increasing demand for Full Time Equivalent (FTE) activities for key pharmaceutical customers, as well as more stability projects from both local operations of Multi-National Companies and overseas organisations.
The expanded laboratory will act as a dedicated cGMP pharmaceutical testing site and is due for completion and validation in Q2 2015.
The Mumbai facility, which is focused on stability studies and dedicated FTE models, will feature three new 100 cu meter capacity stability chambers, HPLCs, dissolutions, Gas Chromatographs and additional general laboratory instruments. Capacity at the site will grow from 423 cu meters to 723 cu meters, while the current 88 strong workforce will ultimately be augmented by an additional 39 members of staff.
“The expansion will bring additional facilities, expertise and personnel to serve our customers’ requirements in Asia,” commented Paul House, Managing Director of SGS India Ltd. “Upon completion, the Mumbai laboratory will be the largest stability testing facility in our Life Science Services network.”
With 21 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly-owned global network, present in North America, Europe, and Asia, to deliver harmonized solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I to IV clinical trial management and services encompassing data management and statistics, PK/PD modeling and simulation, pharmacovigilance and regulatory consultancy.